COMMUNIQUÉS West-GlobeNewswire

Phenomix Sciences and InformedDNA Partner to Advance Genetics-Driven Obesity Care

17/10/2024 - 15:00

Launching at HLTH 2024, the groundbreaking partnership offers payers, health systems, employers, and life science organizations access to personalized obesity care and treatment planning based on a patient’s DNA. MENLO [...]

Intercept Provides Regulatory Update Regarding sNDA for OCALIVA

17/10/2024 - 14:59

MORRISTOWN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A., today announced that the U.S. Food and Drug Administration (FDA) has informed the [...]

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

17/10/2024 - 14:45

PRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced [...]

Sarah Sheikh Joins Cerevance’s Board of Directors

17/10/2024 - 14:30

BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous [...]

New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients

17/10/2024 - 14:30

Groundbreaking Trial Reveals DIFS Increases Neural Activity and Blood Flow in the Hippocampus, Offering Hope for Alzheimer’s Treatment HOUSTON, TX, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL [...]

Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%

17/10/2024 - 14:30

Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients’ eyelids Demodex blepharitis is a significant eyelid disease that impacts approximately 25 [...]

Kane Biotech Announces Exclusive Distribution Agreement With XSONX

17/10/2024 - 14:30

WINNIPEG, Manitoba, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has signed an exclusive five year distribution agreement with XSONX LLC (“ [...]

Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024

17/10/2024 - 14:30

BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect [...]

Alkeus Pharmaceuticals Announces Data Presentations at the American Academy of Ophthalmology (AAO) 2024 Annual Meeting, October 18-21 in Chicago

17/10/2024 - 14:29

Results from Study of Oral Gildeuretinol for Geographic Atrophy Secondary to Age-Related Macular Degeneration to be Presented as Late-Breaker During Retina Subspecialty Day Positive Data from TEASE Program in Stargardt [...]

Sienna Announces Completion of $150 Million Offering of 4.436% Series D Senior Unsecured Debentures

17/10/2024 - 14:16

NOT FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MARKHAM, Ontario, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) [...]

Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan

17/10/2024 - 14:15

WARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for [...]

BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

17/10/2024 - 14:07

Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the NLRP3 inflammasome and [...]

Noom Introduces Innovative In-App Body Scan Technology to Monitor Muscle-Mass Retention During GLP-1 Treatment

17/10/2024 - 14:02

Technology enhances Noom GLP-1 Companion with Muscle Defense™, helping users measure and track progress with a smartphone camera and avoid conditions like sarcopenic obesity NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- [...]

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

17/10/2024 - 14:00

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) [...]

Bright Peak Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of BPT567, a First-in-Class Bifunctional PD1-IL18 Immunoconjugate

17/10/2024 - 14:00

-- BPT567 is the first bifunctional PD1-IL18 immunoconjugate to enter clinical development -- -- Phase 1/2a study will evaluate BPT567 in patients with locally advanced/unresectable or metastatic solid tumors -- BASEL, [...]

ProPhase Labs Announces Positive Updates on Strategic Initiatives Company Anticipates Multiple Liquidity Events in H1 2025

17/10/2024 - 14:00

Projections for Pharmaloz Manufacturing: Approximately $16-17 Million in Revenue, $6-7 Million in Pre-Tax Earnings for 2025 Strategic Partnership Discussions Begin for BE-Smart Esophageal Cancer Test GARDEN CITY, NY, [...]

Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024

17/10/2024 - 14:00

Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and [...]

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

17/10/2024 - 14:00

CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience Limited (“Factor”) today announced an exclusive license and collaboration [...]

Inovalon Launches AI-Powered Converged Record Review To Improve Risk Score Accuracy for Health Plans

17/10/2024 - 14:00

SaaS Solution Uses Advanced Natural Language Processing and Machine Learning to Automate Medical Record Reviews and Enhance Risk Adjustment Performance BOWIE, Md., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inovalon , a leading [...]